Compare · SEER vs WAT
SEER vs WAT
Side-by-side comparison of Seer Inc. (SEER) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SEER and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 360.5x SEER ($113.0M).
- SEER has been more active in the news (7 items in the past 4 weeks vs 6 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 8 for SEER).
- Company
- Seer Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $113.0M
- $40.72B
- 1M return
- +4.06%
- -
- 1Y return
- -1.44%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 1995
- News (4w)
- 7
- 6
- Recent ratings
- 8
- 25
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest SEER
- PRESIDENT & CFO Horn David R. sold $14,809 worth of shares (7,309 units at $2.03), decreasing direct ownership by 1% to 486,650 units (SEC Form 4) to cover taxes
- Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
- SEC Form 10-Q filed by Seer Inc.
- Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
- Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
- Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
- Seer Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Seer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)